Lenvatinib with everolimus [LNV1]

The treatment of previously treated advanced renal cell carcinoma

1. The application has been made by and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy
2. The patient has a confirmed histological diagnosis of renal cell carcinoma with a clear cell component

Note

Note: papillary, chromophobe and Xp11 translocation sub types can be treated as per clear cell pathway

3. The patient has either metastatic disease or inoperable locally advanced disease
4. The patient has previously received only 1 vascular endothelial growth factor (VEGF)-targeted systemic therapy for advanced/metastatic renal cancer* *Patients treated with more than 1 line of VEGF-targeted therapy for advanced/metastatic disease are not eligible for treatment using lenvatinib with everolimus
5. The patient has progressed on previous treatment or within 6 months of discontinuing previous treatment
6. The patient has an ECOG performance status of either 0 or 1* *Patients with a performance status of 2 or more are not eligible for lenvatinib with everolimus
7. The patient has received no previous treatment with either lenvatinib or everolimus
8. The patient either has no brain metastases or, if the patient has brain metastases, then these have been treated and are symptomatically stable
9. Lenvatinib with everolimus will be continued until loss of clinical benefit or unacceptable toxicity or patient choice to stop treatment
10. Where a treatment break of more than 6 weeks beyond the expected 4-weekly cycle length is needed, a treatment break approval form will be completed to restart treatment, which MUST be approved before treatment is recommenced
11. Lenvatinib and everolimus are to be otherwise used as set out in their Summaries of Product Characteristics

NHS funded From: 24 April 2018

Additional information

Form version: -

CDF Managed Access: NA

NICE Technology Appraisal: TA498 (24 January 2018)

Current Form Version

Note

The data on this page was produced using version 1.390 of the CDF list, downloaded from NHS England’s website on 25 March 2026 at 18:00.

If NHS England has published a new version of the CDF List but this site has not yet accessed that, this form may be out of date. Additionally, if any update has occurred without NHS England noting it as a change, this page will be out of date.

Older Form Versions

There are previous versions of this form. These may not all be available on this site.

• LNV1_prior_to_cdf_1.361
• LNV1_prior_to_cdf_1.390